YCT529

Experimental non-hormonal male contraceptive

YCT529
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

YCT529 is an experimental non-hormonal male contraceptive that has been the subject of research due to its potential to provide reversible contraception without the hormonal side effects associated with traditional methods. It is a small molecule that targets the retinoic acid receptor alpha (RAR-α), which plays a crucial role in spermatogenesis.

Mechanism of Action

YCT529 functions by selectively inhibiting the activity of RAR-α, a nuclear receptor that is essential for the regulation of gene expression during the process of sperm production. By blocking this receptor, YCT529 disrupts the normal development of sperm cells, leading to temporary infertility. This mechanism is distinct from hormonal contraceptives, which typically alter levels of testosterone and other hormones, often resulting in side effects such as mood changes and decreased libido.

Development and Research

Research into YCT529 has been conducted primarily in preclinical settings, with studies demonstrating its efficacy in animal models. In these studies, male subjects treated with YCT529 showed a significant reduction in sperm count and motility, leading to effective contraception. Importantly, the effects were found to be reversible, with normal fertility returning after discontinuation of the drug.

Chemical structure of YCT529

Potential Benefits

The development of YCT529 represents a significant advancement in the field of male contraception. Unlike hormonal methods, YCT529 does not interfere with the body's natural hormone levels, potentially reducing the risk of side effects. Additionally, its reversibility makes it an attractive option for men seeking temporary contraception without long-term commitments.

Challenges and Considerations

Despite its promise, YCT529 faces several challenges before it can become a viable contraceptive option. These include ensuring its safety and efficacy in humans, as well as addressing any potential long-term effects. Further clinical trials are necessary to evaluate these aspects and to determine the optimal dosing regimen.

Related Pages

• Contraception
• Male contraceptive
• Retinoic acid receptor
• Spermatogenesis